Despite slim chances that its vaccine will be ready by October, Pfizer has big incentives to hint that it might be
Albert Bourla, chief executive of Pfizer, testifies at a Senate Finance Committee hearing in Washington on Feb. 26, 2019. Despite slim chances that its coronavirus vaccine will be ready by October 2020, Pfizer has big incentives to hint that it might be; Image: Erin Schaff/The New York Times
©2019 New York Times News Service